Understanding Scleritis
Anterior scleritis may look diffusely red, nodular or show tissue damage. Posterior scleritis affects the back wall and can be harder to recognize without imaging. Pain can radiate toward the face or disturb sleep, but presentation varies. [1] [2]
Some cases are associated with rheumatoid arthritis, systemic vasculitis or another inflammatory condition; others have no identified systemic association. Infection and medication or surgical history also need consideration before the disease is labeled idiopathic. [3] [7]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Deep aching or boring pain
Pain can be intense and worsen with eye movement or at night. Ordinary transient irritation is a different symptom pattern, but symptom descriptions alone cannot establish the diagnosis. [1] [2]
Light sensitivity and blur
Light can become uncomfortable and vision may decline when the inflammation or related complications involve other structures. Some anterior cases retain good acuity. [1] [7]
Less visible posterior disease
The eye may look much less red than expected despite pain and visual disturbance. A photograph cannot show inflammation behind the visible front surface. [2] [6]
Surface redness does not show the whole sclera
Original schematic of clinical distinctions; external appearance alone cannot diagnose the condition. [2] [8]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Superficial layer
Episcleritis affects tissue over the white coat.
- Front of sclera
Anterior scleritis may be diffuse, nodular or necrotizing.
- Back of sclera
Posterior disease can require imaging despite a relatively normal-looking front.
What is happening—and what remains uncertain
Scleritis involves inflammation of the scleral tissue and its vessels. In necrotizing disease, tissue can become severely thin or break down; the clinician also checks the nearby cornea, uvea and retina for complications. [3] [7]
Immune-mediated disease and infection can both produce inflammation, but suppressing immunity without identifying infection can be harmful. The investigation and treatment therefore depend on the whole clinical history, not just how red the eye looks. [7]
What can look similar?
Episcleritis is more superficial
Episcleritis affects tissue over the sclera and is usually less painful and less threatening to vision. Severe pain or blurred vision should not be dismissed as a routine recurrence without examination. [1] [8]
Uveitis affects another tissue layer
Uveitis and scleritis can coexist, but they are not synonyms. A slit-lamp and dilated examination help locate the inflammation and its complications. [3]
An infected cornea or sclera needs its own pathway
Previous trauma or surgery, focal infection or worsening during immunosuppression can change the investigation. The treatments for presumed sterile inflammation are not interchangeable with antimicrobial care. [7]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Locate and classify the inflammationExamination distinguishes superficial redness from scleral disease, checks for necrosis and measures vision and pressure. Posterior disease may need ultrasound and retinal imaging. [2] [3]
- Look for a cause with targeted testsHistory includes joint, respiratory, skin and other systemic symptoms, operations, trauma, infections and medicines. Blood tests and imaging should answer clinical questions rather than serve as a self-ordered screening panel. [7]
- Track activity and treatment effectsPain relief, inflammatory control, visual acuity and pressure are monitored separately. A return plan matters because relapses can occur after an apparently quiet interval. [3] [6]
What may help—and what is still being studied
Cause and severity guide early treatment
Noninfectious anterior disease may be treated with anti-inflammatory medicines, while posterior, necrotizing or systemic vasculitic disease may need earlier systemic treatment. Infection changes this approach and may require antimicrobial and surgical care. [3] [7]
What this can mean for daily life
Keep a short symptom record
Describe pain, sleep disruption, light sensitivity and visual change separately. Record whether a change is new rather than assuming that every episode is identical. [1] [6]
Reduce the practical burden of glare
Adjustable lighting, larger text and short breaks can support work while the medical cause is treated. These adaptations do not control scleral inflammation. [1] [7]
Make monitoring workable
Ask for a written medicine and blood-test plan that accommodates work, transport and other illnesses. Discuss side effects promptly instead of silently abandoning treatment. [3]
Use the right community
Ocular-inflammatory-disease peer support can help with coping; a vasculitis group is relevant when that diagnosis is established. Persistent visual difficulty may also justify sight-loss support or rehabilitation. [7]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
Rituximab therapy for refractory scleritis
Nine met the response criteria by 24 weeks; seven required another treatment course to maintain control. [4]
Limits and applicability: Randomization compared two doses, not drug against placebo or standard first-line care. The small refractory cohort cannot establish a universal response rate, optimal drug or long-term safety.
Methotrexate for ocular inflammatory diseases
In the scleritis subgroup, sustained inflammatory suppression by six months was estimated at 56.4%, while corticosteroid-sparing success was 37.3%. [5]
Limits and applicability: Those are different endpoints, not cure rates. Nonrandom treatment selection, specialist-center populations and mixed ocular diseases limit comparisons with other drugs.
Posterior scleritis cohort
Visual acuity improved on average during care, but approximately one third had recurrence after remission. [6]
Limits and applicability: Variable therapies and follow-up prevent causal treatment comparisons or an individual prognosis. The abstract inconsistently describes the 210-day endpoint as remission in results and relapse in conclusion; no timing prediction is adopted here.
Questions researchers still need to answer
- Which first and subsequent treatments best preserve vision and daily function for each scleritis subtype?
- Can prospective studies distinguish who needs early biologic treatment from those who do well with a simpler approach?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
College of Optometrists: scleritis
January 2026 public summary explains anterior versus posterior disease and urgent referral. The detailed professional section requires a login.
Ocular Immunology and Uveitis Foundation: support
Official support directory explicitly includes scleritis. Peer discussion is not medical advice; private social groups require their own admission. Older clinical Q&A on the same site is not a current prescribing guide.
Connections listed by the organization.
Vasculitis Foundation
Useful when an associated vasculitis has been diagnosed. Facilitated meetings and affiliated community groups; this does not imply that every case of scleritis is vasculitis.
Connections listed by the organization.
RNIB community connection and wellbeing
Broader peer connection for people affected by persistent sight difficulties and their families; not a condition-specific group or medical advice. Check each service’s geographic eligibility.
Connections listed by the organization.
Questions you may still have
Is scleritis the same as episcleritis?
No. They involve different tissue depths and usually differ in risk and treatment. Severe pain or visual change needs assessment even after a previous benign diagnosis. [1] [8]
Must the eye be very red?
No. Posterior disease can leave the visible front of the eye relatively normal, and redness cannot measure severity. [2]
Does this mean I have an autoimmune disease?
Not necessarily. An association may be found, but infection, other causes or no identified systemic disease are also possible. [3] [7]
Does improvement mean it cannot recur?
No. Relapse can occur after inflammatory control. Follow-up and an agreed return plan remain important. [6]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- Moorfields Eye Hospital: uveitis page, separate scleritis section (n.d.; institution).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Public page checked - College of Optometrists: Scleritis, version12 (2026; guideline).
Public explanatory section and revision dates opened; member-only clinical text not accessed.
Checked 2026-10-24 · Public page checked - Abdel-Aty and colleagues: Management of noninfectious scleritis (2022; review).
Indexed original review sections checked; direct PMC returned browser challenge. Secondary synthesis, not a new treatment cohort.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Suhler and colleagues: Rituximab therapy for refractory scleritis (2014; trial).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Gangaputra and colleagues: Methotrexate for ocular inflammatory diseases (2009; observational).
Indexed original methods/results including 56people84 eyes checked; direct PMC challenge. Mixed-disease cohort and nonrandom treatment.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Lavric and colleagues: Posterior scleritis—cohort of 114 patients (2016; observational).
Original indexed abstract checked; internally inconsistent timing label is not repeated as a prediction.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Greenbaum and Castiblanco: Update on scleritis diagnosis and management (2026; review).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Full text checked - Moorfields Eye Hospital: Episcleritis (n.d.; institution).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.